Rhinovirus C immunogenic peptides
A peptide comprising the rhinovirus immunogen peptide of the rhinovirus structural protein 1 (VP1) of rhinovirus C and related vaccines and therapeutic compositions is disclosed.
1. A composition comprising a peptide of the rhinovirus structural protein 1 (VP1) of rhinovirus C and a heterologous carrier protein, wherein the peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1, 3, 6, 8, 11, 13, 15, 17, 19, 21, 23, 25, 27, 30, 33, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 57, 59, 61, 63, 65, 67, 48, 71, 73, 75, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 117, 119, 121, 123, 125, and 127.
2. The composition of claim 1 , wherein the peptide is bound to the carrier protein.
3. The composition of claim 1 , wherein the peptide comprises SEQ ID NO: 1 (YKPNSSGPDEHVLKD).
4. A vaccine comprising a rhinovirus immunogen peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1, 3, 6, 8, 11, 13, 15, 17, 19, 21, 23, 25, 27, 30, 33, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 57, 59, 61, 63, 65, 67, 48, 71, 73, 75, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 117, 119, 121, 123, 125, and 127, and an adjuvant or heterologous carrier protein.
5. A pharmaceutical composition comprising the vaccine of claim 4 .
6. An expression vector comprising a polynucleotide operably linked to a heterologous transcriptional regulatory element wherein the polynucleotide encodes an immunogen peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1, 3, 6, 8, 11, 13, 15, 17, 19, 21, 23, 25, 27, 30, 33, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 57, 59, 61, 63, 65, 67, 48, 71, 73, 75, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 117, 119, 121, 123, 125, and 127.
7. The expression vector of claim 6 , wherein the immunogen peptide is SEQ ID NO: 1 (YKPNSSGPDEHVLKD).
8. An isolated cell comprising the expression vector of claim 6 .
9. The isolated cell of claim 8 , wherein the cell expresses the peptide.
10. The peptide expressed by the isolated cell of claim 9 .
11. A method of eliciting an immune response against rhinovirus in a subject, the method comprising administering by injection to the subject a composition of claim 1 .
12. A method for immunizing a subject against rhinovirus infection, which comprises administering by injection to a subject an effective amount of the pharmaceutical composition of claim 5 .
13. The method of claim 12 , wherein the rhinovirus infection is a human rhinovirus C virus.
14. The method of claim 12 , wherein the vaccine comprises the peptide coupled to a carrier molecule.
15. A method of eliciting neutralizing antibodies against rhinovirus C, the method comprising the steps of injecting into a subject an effective amount of the composition of claim 1 .